Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
about
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityCombating Non-nucleoside Reverse Transcriptase Inhibitor Resistance with a Focus On Etravirine (Intelence) for HIV-1 InfectionCurrent perspectives on HIV-1 antiretroviral drug resistanceA comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutantsHIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateTransmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 PolymorphismClosing the door to human immunodeficiency virus.Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patientsProfile of etravirine for the treatment of HIV infectionCombination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutationsDolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 studyEvolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infectionThree-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.Role of tipranavir in treatment of patients with multidrug-resistant HIVDistinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients.Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.Hypersensitivity reactions to HIV therapy.Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimensRandomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 InfectionAntiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committeeEndothelial, inflammatory, coagulation, metabolic effects and safety of etravirine in HIV-uninfected volunteers.Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South AfricaEarly antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings.Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism
P2860
Q24628212-70C7B68B-7F9F-4E12-8A9A-D3D2575C3B47Q24648456-D27DCFE7-9841-4DDD-B5D5-EB26F15C810FQ26852626-B82C4C27-554C-480F-8872-52ABAB1F72E8Q27675380-E2427BA5-7549-4BFF-A648-60C72EB1B489Q28250395-C706425D-F75D-4EC7-A4D2-9F7D5F9F3580Q28476489-A2F0461D-9064-4655-BB22-FB3124E4816BQ28552997-2BCD9109-9B9D-4A9C-B6A6-B16C22C0A911Q30428089-BE296C98-C5F4-40F7-90F5-3B2A55D0F48AQ33413634-DAE83055-5FB9-4447-B9FF-133CA08093D4Q33558937-131EF542-2D2F-4049-A400-5E98609E6771Q33635039-47F23717-8DDE-47A6-898A-1CF4E0547DA2Q33768822-AE03E52B-D7DD-4425-B688-8BD22606B843Q33775397-A48768A2-1C67-4525-B9E9-144ADD7A5792Q33850152-B1C54DD1-D659-47FD-BE59-EFD7462ADE57Q33867773-AED750A1-118E-47BD-8ECB-E02D6E02A250Q33880221-74BA25C4-CDCC-4FF3-AF8D-D655A0AA13E9Q33931265-B77BD207-596A-4AC8-8C61-E17A6F465D71Q33973857-39059D2D-D8A7-4069-AECF-CB5C8A8205C0Q34051325-14486E92-CD1E-4EF1-B132-56FE3295C1B8Q34102246-CEBE6989-AE0B-459B-9FC2-58FCF5708156Q34187649-DB377FBA-259D-40D0-9075-01596E8EAD2EQ34289973-3FAF1EB5-707D-4997-8FEA-E18CE9C3346CQ34303603-2C014270-3274-44F3-97DA-62228480C969Q34447780-6BA950CB-689C-47C2-BE73-8989F873DBBEQ34911718-E64D97AB-B437-4D13-8A0B-DD5EC819D726Q34932654-B53DD434-D428-4295-A578-F0B0305E8750Q34976463-C87C3B99-1530-4DB0-99D1-1C4332DA30FDQ35004847-F00D0371-CA5A-4F01-AD1B-CADFE382DAEEQ35087745-C064F1A9-295E-4E6E-8C2B-3E3C3A230A6DQ35105844-B007204D-7EFE-4D3F-BDDD-4E689D5222D0Q35111300-5339551F-02C2-42E6-90E4-363DC26540F6Q35124959-71D02431-41E6-4955-A27E-EE8A227ECA4EQ35127398-9CC5DE70-3C46-4700-A140-D463C3060B5FQ35217629-B292762F-D662-46CD-810D-073F1877A406Q35244295-701F44EA-5720-40A1-907F-65CE5BC32AB1Q35542299-569E1F45-05F6-4B90-9E55-D823B856D408Q35557235-FD2FEE8A-A505-4781-A14A-FB818AAA7881Q35610449-4F6FE5C4-F50E-4ADD-A63C-9FDD03792241Q35636520-237D65FB-5DD5-46AF-BD19-E09A846B7485Q35846917-5212B792-1C1A-42B3-AF68-D10C6F3511D7
P2860
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Efficacy and safety of TMC125 ...... ind, placebo-controlled trial.
@en
Efficacy and safety of TMC125 ...... ind, placebo-controlled trial.
@nl
type
label
Efficacy and safety of TMC125 ...... ind, placebo-controlled trial.
@en
Efficacy and safety of TMC125 ...... ind, placebo-controlled trial.
@nl
prefLabel
Efficacy and safety of TMC125 ...... ind, placebo-controlled trial.
@en
Efficacy and safety of TMC125 ...... ind, placebo-controlled trial.
@nl
P2093
P50
P1433
P1476
Efficacy and safety of TMC125 ...... ind, placebo-controlled trial.
@en
P2093
Arend Moll
Benny Baeten
Benoit Trottier
Brian Woodfall
DUET-2 study group
Goedele de Smedt
Greet Beets
Johan Vingerhoets
Margaret Johnson
Monika Peeters
P356
10.1016/S0140-6736(07)61048-4
P407
P577
2007-07-01T00:00:00Z